LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-19
Case ID: NM_006231.4_c.62_9C_T_20261119_171249
Framework: ACMG/AMP 2015 with custom gene-specific criterion specifications
Variant classification summary

NM_006231.4:c.62+9C>T

POLE  · NP_006222.2:p.?  · NM_006231.4
GRCh37: chr12:133263831 G>A  ·  GRCh38: chr12:132687245 G>A
Gene: POLE Transcript: NM_006231.4
Final call
VUS
PM2 moderate
All criteria require review: For research and educational purposes only.
Gene
POLE
Transcript
NM_006231.4
Protein
NP_006222.2:p.?
gnomAD AF
6.758967121680333e-07 (v4.1)
ClinVar
Likely benign
OncoKB
Interpretation summary
Generated evidence synthesis
1
PM2 Moderate: the highest relevant allele frequency is 1.04e-5, below the supplied 0.0001 cutoff, with one allele and no homozygotes.
Final determination: Under the local POLE framework's ACMG/AMP combination rules, PM2 Moderate alone satisfies no pathogenic, likely pathogenic, benign, or likely benign rule, resulting in VUS.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: c.62+9C>T is an intronic substitution outside the PVS1-named null-variant classes, including canonical ±1/2 splice sites, and has protein consequence p.? .
pvs1_variant_assessment pvs1_gene_context
PS1 N/A Not applicable: the intronic c.62+9C>T variant has protein consequence p.?, so no same-amino-acid substitution exists for comparison.
PS2 Not assessed Not assessed: no documented affected proband, family history, or confirmed maternity and paternity for this variant.
PS3 Not assessed Not assessed: no variant-specific validated in vitro or in vivo functional assay result is available to establish a damaging effect.
PS4 Not met Not met: the POLE rule requires an exact recurrent missense hotspot with combined endometrial-cancer count >=10, but this intronic c.62+9C>T variant is not listed.
vcep_path_250_323 vcep_path_250_323_s002 vcep_path_250_323_s001
PM1 N/A Not applicable: the POLE framework restricts PM1 to exact exonuclease-domain missense substitutions, while c.62+9C>T is intronic and p.? .
vcep_path_250_323 vcep_path_250_323_s002 vcep_path_250_323_s001
PM2 Met Met at Moderate: the highest relevant AF is 1.04e-5, below the supplied 0.0001 PM2 cutoff, with one allele and no homozygotes.
gnomad_v2 gnomad_v4
PM3 Not assessed Not assessed: no affected-proband observation or parental/offspring testing establishes this variant in trans with a pathogenic variant.
PM4 N/A Not applicable: c.62+9C>T is an intronic single-nucleotide substitution with protein consequence p.?, not a documented in-frame indel or stop-loss variant.
pvs1_variant_assessment
PM5 N/A Not applicable: the intronic c.62+9C>T variant has protein consequence p.?, so PM5 cannot compare alternate missense changes at one residue.
PM6 Not assessed Not assessed: no affected patient with an assumed de novo variant and incomplete parental testing is documented.
PP1 Not assessed Not assessed: no affected relatives or informative variant segregation data are documented for evaluating co-segregation.
PP2 N/A Not applicable: PP2 is restricted to missense variants, whereas c.62+9C>T is intronic and produces protein consequence p.?.
PP3 N/A Not applicable: the POLE PP3 rule is restricted to exact missense variants, whereas c.62+9C>T is intronic with predicted protein consequence p.?.
vcep_path_250_323 vcep_path_250_323_s002 vcep_path_250_323_s003 vcep_path_250_323_s004
PP4 Not assessed Not assessed: no patient phenotype or family-history details were available to test the PP4 specificity requirement.
PP5 Not met Not met: ClinVar has one single-submitter Likely benign record and zero expert-panel submissions, not an expert-panel Pathogenic or Likely pathogenic classification.
clinvar PMID:28492532
BA1 Not met Not met: observed allele frequencies are 6.76e-7 to 1.04e-5, far below the 0.05 BA1 threshold.
gnomad_v2 gnomad_v4
BS1 Not met Not met: the highest observed AF is 1.04e-5, below the supplied 0.01 BS1 default and not greater than expected for the disorder.
gnomad_v2 gnomad_v4
BS2 Not assessed Not assessed: no homozygotes were observed, but the single carrier is not documented as a healthy adult under a fully penetrant early-onset disease model.
gnomad_v2 gnomad_v4
BS3 Not assessed Not assessed: no variant-specific validated in vitro or in vivo functional assay result is available to establish a non-damaging effect.
BS4 Not assessed Not assessed: no affected relatives lacking the variant are documented to demonstrate absence of segregation.
BP1 N/A Not applicable: BP1 is restricted to missense variants, whereas c.62+9C>T is intronic and produces protein consequence p.?.
BP2 Not assessed Not assessed: no phase data establish this variant in trans or cis with a pathogenic variant.
BP3 N/A Not applicable: c.62+9C>T is an intronic single-nucleotide substitution, not an in-frame deletion or insertion in a repetitive region without known function.
pvs1_variant_assessment
BP4 N/A Not applicable: the POLE BP4 rule is restricted to exact missense variants, whereas c.62+9C>T is intronic with predicted protein consequence p.?.
vcep_path_250_323 vcep_path_250_323_s002 vcep_path_250_323_s003 vcep_path_250_323_s004
BP5 Not assessed Not assessed: no affected case with an independently established alternate molecular basis for disease was available.
clinvar
BP6 Not met Not met: the exact ClinVar record is single-submitter Likely benign with zero expert-panel submissions, so it does not satisfy the BP6 evidence requirement.
clinvar PMID:28492532
BP7 N/A Not applicable: BP7 requires a synonymous variant, but c.62+9C>T is intronic and has predicted protein consequence p.?.
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.